Evommune inks molecular glue deal worth $1.1B biobucks to fill pipeline gap
Evommune is paying Hinova Pharmaceuticals $30 million to license the China biopharma’s oral molecular glue degrader for autoimmune diseases. The…
Evommune is paying Hinova Pharmaceuticals $30 million to license the China biopharma’s oral molecular glue degrader for autoimmune diseases. The…